[1] |
Li T, Liu ZH, Li K, et al. Evaluation of the vaginal microbiome in clinical diagnosis and management of vaginal infectious diseases[J]. Chin Med J (Engl), 2019, 132(9):1100-1103. DOI: 10.1097/CM9.0000000000000211.
|
[2] |
Lu Y, Xu X, Nong XH, et al. Detection of high-risk human papillomavirus DNA in sentinel lymph nodes of patients with cervical cancer[J]. Oncol Lett, 2020, 19(3):2317-2325. DOI: 10.3892/ol.2020.11337.
|
[3] |
Chao X, Sun T, Wang S, et al. Research of the potential biomarkers in vaginal microbiome for persistent high-risk human papillomavirus infection[J]. Ann Transl Med, 2020, 8(4):100. DOI: 10.21037/atm.2019.12.115.
|
[4] |
Weston G, Dombrowski C, Harvey MJ, et al. Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation[J]. BMJ Open, 2020, 10(3):e031303. DOI: 10.1136/bmjopen-2019-031303.
|
[5] |
Vos RA, Pasmans H, Tymchenko L, et al. High seroprevalence of multiple high-risk human papillomavirus types among the general population of Bonaire, St. Eustatius and Saba, Caribbean Netherlands[J]. Vaccine, 2020, 38(13):2816-2826. DOI: 10.1016/j.vaccine.2020.02.017.
|
[6] |
Castle PE, Varallo JE, Bertram MM, et al. High-risk human papillomavirus prevalence in self-collected cervicovaginal specimens from human immunodeficiency virus (HIV)-negative women and women living with HIV living in Botswana[J]. PLoS One, 2020, 15(2):e0229086. DOI: 10.1371/journal.pone.0229086.
|
[7] |
Pańczyszyn A, Boniewska-Bernacka E, Gīąb G. Telomere length in leukocytes and cervical smears of women with high-risk human papillomavirus (HR HPV) infection[J]. Taiwan J Obstet Gynecol, 2020, 59(1):51-55. DOI: 10.1016/j.tjog.2019.11.007.
|
[8] |
Manley KM, Luker R, Park C. An audit of liquid-based cytology samples reported as high-risk human papillomavirus and borderline nuclear change in endocervical cells[J]. Cytopathology, 2020, 31(2):130-135. DOI: 10.1111/cyt.12803.
|
[9] |
Sangpichai S, Patarapadungkit N, Pientong C, et al. Chlamydia trachomatis infection in high-risk human papillomavirus based on cervical cytology specimen[J]. Asian Pac J Cancer Prev, 2019, 20(12):3843-3847. DOI: 10.31557/APJCP.2019.20.12.3843.
|
[10] |
Zhao S, Zhao XL, Hu SY, et al.Comparison of high-risk human papillomavirus infection rate and genotype distribution between Han and Mongolian women[J]. Chin J Epidemiol, 2019, 40(11):1439-1444. DOI: 10.3760/cma.j.issn.0254-6450.2019.11.018.
|
[11] |
Cao M, Wang Y, Wang D, et al. Increased high-risk human papillomavirus viral load is associated with immunosuppressed microenvironment and predicts a worse long-term survival in cervical cancer patients[J]. Am J Clin Pathol, 2020, 153(4):502-512. DOI: 10.1093/ajcp/aqz186.
|
[12] |
Negi SS, Bhargava A, Singh P, et al. Predominance of high-risk human papillomavirus genotype 16 and 39 in women with premalignant and malignant cervical pathology from Raipur, Chhattisgarh: clinical evaluation of tagging oligonucleotide cleavage and extension mediated genotyping assay[J]. Indian J Med Microbiol, 2019, 37(2):255-262. DOI: 10.4103/ijmm.IJMM_19_162.
|
[13] |
Nikouyan N, Farhadi A, Gorzin AA, et al. A fluorometric hybridization assay for detecting and genotyping high-risk human papillomavirus 16 and 18 in archival tissues of cervical specimens[J]. Braz J Microbiol, 2020, 51(1):161-168. DOI: 10.1007/s42770-019-00137-8.
|
[14] |
Kim J, Jun SY. Analytic performance of PANArray HPV and HPV 9G DNA chip tests for genotyping of high-risk human papillomavirus in cervical ThinPrep PreservCyt samples[J]. PLoS One, 2019, 14(10):e0224483. DOI: 10.1371/journal.pone.0224483.
|
[15] |
|
[16] |
|
[17] |
Surriabre P, Torrico A, Vargas T, et al. Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention[J]. BMC Infect Dis, 2019, 19(1):842. DOI: 10.1186/s12879-019-4527-9.
|
[18] |
|
[19] |
Siegler E, Reichman Y, Kugelman N, et al. Low-risk human papillomavirus types in cervical intraepithelial neoplasia 2-3 and in invasive cervical cancer patients[J]. J Low Genit Tract Dis, 2019, 23(4):248-252. DOI: 10.1097/LGT.0000000000000486.
|
[20] |
Salambanga C, Zohoncon TM, Traoré I, et al. High prevalence of high-risk human papillomavirus (HPV) infection among sexually active women in Ouagadougou[J]. Med Sante Trop, 2019, 29(3):302-305. DOI: 10.1684/mst.2019.0920.
|
[21] |
Luckett R, Mogowa N, Li HJ, et al. Performance of two-stage cervical cancer screening with primary high-risk human papillomavirus testing in women living with human immunodeficiency virus[J]. Obstet Gynecol, 2019, 134(4):840-849. DOI: 10.1097/AOG.0000000000003496.
|
[22] |
杨少岩,赵卫东. 阴道微环境改变与宫颈癌相关性的研究进展[J]. 深圳中西医结合杂志,2017, 27(6):4.
|